Seed Therapeutics
  • Mission
  • Drug Discovery
  • Leadership
  • Pipeline
  • Communications
  • Careers
Select Page

BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly

by Andrey Alimetov | Nov 13, 2020 | Press Releases

info@seedtherapeutics.com info@seedtherapeutics.com   PRESS RELEASES BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly Seed Therapeutics to Use Proprietary “Molecular Glue” Protein Degradation Technology...

Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer

by Andrey Alimetov | Oct 14, 2020 | Press Releases

info@seedtherapeutics.com  info@seedtherapeutics.com   PRESS RELEASES Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer “Molecular Glue” Protein Degradation Serves as Alternative Approach...

Recent Posts

  • SEED Therapeutics Highlights Breakthrough Advances in Targeted Protein Degradation at AACR 2025
  • SEED Therapeutics Reports Breakthroughs for Two Targeted Protein Degradation Projects at AACR Annual Meeting in Chicago
  • SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
  • Nature: Protein degraders push into novel target space
  • SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors

Recent Comments

    Seed Therapeutics logo
    • LinkedIn
    • Twitter

    ©2023 All rights reserved – SEED Therapeutics, Inc.         Privacy Policy | Terms of Use | Accessibility Statement

    411 Swedeland Road, Suite 1000 King of Prussia, PA 19406, United States           info@seedtherapeutics.com

    We use cookies to ensure that we give you the best experience on our website. Please click “OK” to continue or read our Privacy & Cookie Policy.OkPrivacy Policy